WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock

Open Broker Account
$1.76-0.04 (-2.22%)
Updated Dec 8, 2022
ADAP Price
$1.76
Fair Value Price
$2.72
Market Cap
$288.92M
52 Week Low
$1.01
52 Week High
$4.17
P/E
-1.63x
P/B
2.55x
P/S
10.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.54M
Earnings
-$175.06M
Gross Margin
100%
Operating Margin
-988.49%
Profit Margin
-998.3%
Debt to Equity
1.93
Operating Cash Flow
-$10M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ADAP Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADAP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ADAP ($1.76) is undervalued by 35.35% relative to our estimate of its Fair Value price of $2.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADAP ($1.76) is significantly undervalued by 35.35% relative to our estimate of its Fair Value price of $2.72 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ADAP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADAP due diligence checks available for Premium users.

Be the first to know about important ADAP news, forecast changes, insider trades & much more!

ADAP News

Valuation

ADAP fair value

Fair Value of ADAP stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$2.72
Undervalued by
35.35%
ADAP ($1.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADAP ($1.76) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADAP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ADAP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.63x
Industry
13.31x
Market
21.39x

ADAP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.55x
Industry
4.98x
ADAP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ADAP's financial health

Profit margin

Revenue
$7.0M
Net Income
-$41.4M
Profit Margin
-591.1%
ADAP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADAP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$332.2M
Liabilities
$218.9M
Debt to equity
1.93
ADAP's short-term assets ($264.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADAP's short-term assets ($264.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADAP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADAP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$48.2M
Investing
$28.9M
Financing
$1.5M
ADAP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ADAP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ADAP$288.92M-2.22%-1.63x2.55x
VKTX$288.35M+0.27%-4.64x1.91x
NAMS$286.54M+5.24%-44.70x-24.56x
ALPN$285.59M+0.48%-3.46x1.57x
TYRA$292.43M-0.72%9.90x1.09x

Adaptimmune Therapeutics Stock FAQ

What is Adaptimmune Therapeutics's quote symbol?

NASDAQ: ADAP) Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol ADAP. Adaptimmune Therapeutics stock quotes can also be displayed as NASDAQ: ADAP.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.

What is the 52 week high and low for Adaptimmune Therapeutics (NASDAQ: ADAP)?

(NASDAQ: ADAP) Adaptimmune Therapeutics's 52-week high was $4.17, and its 52-week low was $1.01. It is currently -57.74% from its 52-week high and 74.26% from its 52-week low.

How much is Adaptimmune Therapeutics stock worth today?

(NASDAQ: ADAP) Adaptimmune Therapeutics currently has 982,974,108 outstanding shares. With Adaptimmune Therapeutics stock trading at $1.76 per share, the total value of Adaptimmune Therapeutics stock (market capitalization) is $288.92M.

Adaptimmune Therapeutics stock was originally listed at a price of $16.00 in May 6, 2015. If you had invested in Adaptimmune Therapeutics stock at $16.00, your return over the last 7 years would have been -89%, for an annualized return of -27.04% (not including any dividends or dividend reinvestments).

How much is Adaptimmune Therapeutics's stock price per share?

(NASDAQ: ADAP) Adaptimmune Therapeutics stock price per share is $1.76 today (as of Dec 8, 2022).

What is Adaptimmune Therapeutics's Market Cap?

(NASDAQ: ADAP) Adaptimmune Therapeutics's market cap is $288.92M, as of Dec 9, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adaptimmune Therapeutics's market cap is calculated by multiplying ADAP's current stock price of $1.76 by ADAP's total outstanding shares of 982,974,108.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.